A61K 39 - Medicinal preparations containing antigens or antibodies

Patents for A61K 39 - Medicinal preparations containing antigens or antibodies (182,248)
12/2004
12/23/2004	CA2527863A1 Cell surface protein associated with human chronic lymphocytic leukemia
12/23/2004	CA2527830A1 Therapeutic vaccine compositions for the treatment of type 1 diabetes
12/23/2004	CA2527735A1 Functionally reconstituted viral membranes containing adjuvant
12/23/2004	CA2527621A1 Method of inhibiting tumor growth with anti-tissue factor antibodies
12/23/2004	CA2526753A1 Sdr proteins from staphylococcus capitis and their use in preventing and treating infections
12/23/2004	CA2526416A1 Polyanionic polymer adjuvants for haemophilus influenza b saccharide vaccines
12/23/2004	CA2525966A1 Novel immunomodulating peptide
12/23/2004	CA2525917A1 Compositions and methods including a recombinant human mab that promotes cns remyelination
12/23/2004	CA2525778A1 T cell epitopes useful in a severe acute respiratory syndrome (sars) virus vaccine and as diagnostic tools and methods for identifying same
12/23/2004	CA2525517A1 Use of prion conversion modulating agents
12/23/2004	CA2524325A1 Method of altering the binding specificity of plasma proteins by oxidation-reduction reactions
12/23/2004	CA2520148A1 Compositions and methods for treating coronavirus infection and sars
12/23/2004	CA2519875A1 Method of tumor regression with vegf inhibitors
12/23/2004	CA2515369A1 Listeria attenuated for entry into non-phagocytic cells, vaccines comprising the listeria, and methods of use thereof
12/23/2004	CA2514288A1 Compositions and methods employing alternative reading frame polypeptides for the treatment of cancer and infectious disease
12/22/2004	EP1489183A1 Polynucleotide encoding a polypeptide having heparanase activity and expression of same in transduced cells
12/22/2004	EP1489170A1 Transporter selectively transporting sulfate conjugate and its gene
12/22/2004	EP1489165A1 Recombinant fowlpox vaccine for protection against marek's disease
12/22/2004	EP1489164A1 Recombinant vaccinia viruses with modified F3 genes, uses thereof
12/22/2004	EP1489099A2 Antibodies that bind the CD40CR receptor
12/22/2004	EP1489092A1 Modified Bordetella adenylate cyclase comprising or lacking CD11b/CD18 interaction domain and uses thereof
12/22/2004	EP1488806A2 A blocking monoclonal antibody to VLA-1 and its use for the treatment of vascular disorders
12/22/2004	EP1488805A2 CD28 pathway immunoregulation
12/22/2004	EP1488799A2 Soluble lymphotosin-Beta receptors and anti-lymphotoxin receptor and ligand antibodies as therapeutic agents for the treatment of immunological disease
12/22/2004	EP1488239A2 Methods and compositions for the identification, assessment, and therapy of small cell lung cancer
12/22/2004	EP1488231A2 Methods for the identification of compounds useful for the suppression of chronic neuropathic pain and compositions thereof
12/22/2004	EP1487998A2 Methods for diagnosing and treating schizophrenia
12/22/2004	EP1487992A2 Central airway administration for systemic delivery of therapeutics
12/22/2004	EP1487991A2 Cancer-linked gene as target for chemotherapy
12/22/2004	EP1487986A2 METHOD OF PREPARING A TREATMENT PRODUCT, TREATMENT PRODUCT AND A PLASMID CONSTRUCT
12/22/2004	EP1487984A1 Dna vaccines encoding cea and a cd40 ligand and methods of use thereof
12/22/2004	EP1487983A2 Prevention of recurrence and metastasis of cancer
12/22/2004	EP1487972A2 Mn/ca ix-specific monoclonal antibodies generated from mn/ca ix-deficient mice and methods of use
12/22/2004	EP1487877A2 Compositions and methods for the diagnosis and treatment of tumor
12/22/2004	EP1487876A1 The use of an epitope of vascular endothelial growth factor receptor kdr/flk-1
12/22/2004	EP1487875A2 Antibody that binds to a dimer of a prion protein for the treatment of tse infection
12/22/2004	EP1487869A1 Novel allergen
12/22/2004	EP1487865A2 USES OF MAMMALIAN CYTOKINEi; RELATED REAGENTS
12/22/2004	EP1487857A1 Lymphatic and blood endothelial cell genes
12/22/2004	EP1487856A2 Human antibodies specific to kdr and uses thereof
12/22/2004	EP1487854A2 Novel isoforms of vascular endothelial ell growth inhibitor
12/22/2004	EP1487852A1 Anti-protozoal vaccine
12/22/2004	EP1487788A1 Diaminoacid-aminoacid-polyamine based gemini surfactant compounds
12/22/2004	EP1487541A2 Use of il-18 inhibitors for the treatment and/or prevention of peripheral vascular diseases
12/22/2004	EP1487501A2 A phosphatase associated with metastasis
12/22/2004	EP1487497A2 Use of urea-adjuvated polypeptides for diagnosis, prophylaxis and treatment
12/22/2004	EP1487493A2 Conjugates of therapeutic or cytotoxic agents and biologically active peptides
12/22/2004	EP1487492A1 The prevention or treatment of cancer using integrin alphavbeta3 antagonists in combination with other agents
12/22/2004	EP1487491A2 Novel of cytokine inhibitors
12/22/2004	EP1487490A2 Combination methods of inhibiting tumor growth with a vascular endothelial growth factor receptor antagonist
12/22/2004	EP1487489A2 METHODS OF PREVENTING OR TREATING DISORDERS BY ADMINISTERING AN INTEGRIN avb3 ANTAGONIST IN COMBINATION WITH AN HMG-CoA REDUCTASE INHIBITOR OR A BISPHOSPHONATE
12/22/2004	EP1487488A1 Specific antibodies to amyloid beta peptide, pharmaceutical compositions and methods of use thereof
12/22/2004	EP1487487A2 Methods and compositions for prevention, diagnosis, and treatment of cancer using bispecific molecules
12/22/2004	EP1487486A2 Imidazoquinolineamines as adjuvants in hiv dna vaccination
12/22/2004	EP1487485A2 Imidazoquinoline adjuvants for vaccines
12/22/2004	EP1487484A2 Use of mixtures of lipopeptides for vaccine production
12/22/2004	EP1487483A2 Chimeric infectious dna clones, chimeric porcine circoviruses and uses thereof
12/22/2004	EP1487482A2 Dna vaccine against proliferating endothelial cells and methods of use thereof.
12/22/2004	EP1487481A2 Methods of treating nerve entrapment syndromes
12/22/2004	EP1487477A2 Methods of using flt3-ligand in immunization protocols
12/22/2004	EP1487436A1 Combination therapy for treating, preventing or managing proliferative disorders and cancers
12/22/2004	EP1487428A2 Amino-substituted (e)-2,6-dialkoxystyryl 4-substituted benzylsulfones for treating proliferative disorders
12/22/2004	EP1487280A1 Compositions and methods for eliciting an immune response to gram-negative bacterial infections
12/22/2004	EP1082135B1 Use of hyaluronic acid polymers for mucosal delivery of vaccine antigens and adjuvants
12/22/2004	EP0906110B1 Dna vaccine formulations
12/22/2004	EP0862584B1 Production of antibodies
12/22/2004	EP0832253B9 Nucleic acid respiratory syncytial virus vaccines
12/22/2004	EP0817648B1 Vascular endothelial cell growth factor antagonists
12/22/2004	EP0815236B1 Haemophilus adhesion proteins
12/22/2004	CN1556863A Methods and compositions relating to HPV-associated pre-cancerous and cancerous growths, including CIN
12/22/2004	CN1556857A Novel peptides of the respiratory syncytial virus (RSV) G protein and their use in a vaccine
12/22/2004	CN1556856A Vaccines from infectious agents
12/22/2004	CN1181201C LAG-3 splice variants
12/22/2004	CN1181097C Monochain antibody with dual specificities possessing activity for restraining adherence and aggregation of blood platelets
12/22/2004	CN1181086C Aminoalkyl glucosamine phosphate compounds and their use as adjuvants and immunoeffectors
12/22/2004	CN1180843C Polyepitope vaccines
12/22/2004	CN1180839C Powdery preparation containing polymeric medicine for mucosal administration
12/21/2004	US6833438 Involves STEAP (six transmembrane epithelial antigen of the prostate); used in diagnosis, therapy and management of various cancers, including prostate cancer, colon cancer, bladder cancer, ovarian cancer and pancreatic cancer
12/21/2004	US6833264 Hyaluronan synthase gene and uses therof
12/21/2004	US6833262 Polypeptide having amidolytic activity for a serpin
12/21/2004	US6833253 Nucleotide sequences coding polypeptides for use in the prevention of microorganismal infections
12/21/2004	US6833136 Treatment of Pythium insidiosum infections; animal model for evaluating Pythium insidiosum vaccines
12/21/2004	US6833135 DNA integration into “Mycobacterium spp.” genome by trans-complementation using a site-specific integration system
12/21/2004	US6833134 Immunization of dairy cattle with GapC protein against Streptococcus infection
12/21/2004	US6833133 Escape mutants of Newcastle disease virus as marker vaccines
12/21/2004	US6833132 Method of stimulating epithelial cells using keratinocyte growth factor (KGF) and method of inhibiting KGF activity
12/21/2004	US6833131 Antivenom immunesera
12/19/2004	CA2454705A1 Prevention of uveitis
12/16/2004	WO2004109291A2 Method for diagnosis and therapy of hazelnut-induced systemic reaction
12/16/2004	WO2004108940A2 Viral genome vectors
12/16/2004	WO2004108939A2 Bav packaging regions and e1 transcriptional control regions
12/16/2004	WO2004108937A1 Cell surface expression vector of sars virus antigen and microorganisms transformed thereby
12/16/2004	WO2004108923A1 Cd47 partal peptdie and anti-shps-1 monoclonal antibody
12/16/2004	WO2004108909A1 Composition for stabilizing survival of transplanted hematopoietic stem cell, kit for obtaining the composition, method of stabilizing survivial of transplanted hematopoietic stem cell, human monoclonal antibody or human polyclonal antibody and method of producing the same, gene encoding human monoclonal antibody and transf
12/16/2004	WO2004108885A2 Fc chimeric proteins with anti-hiv drugs
12/16/2004	WO2004108759A1 Hypoallergenic hevein for immunotherapy of latex allergy
12/16/2004	WO2004108756A2 Sars coronavirus peptides and uses thereof
12/16/2004	WO2004108753A1 Immunomodulating compositions, uses therefor and processes for their production
12/16/2004	WO2004108157A2 Use of myostatin (gdf8) inhibitors in conjunction with corticosteroids for treating neuromuscular disorders
12/16/2004	WO2004108156A1 A INTRACUTANEOUS INJECTION COMBINED VACCINE INCLUDED HeVac AND BCG AND ITS PREPARATION METHOD

1 ... 1099 1100 1101 1102 1103 1104 1105 1106 1107 1108 1109 1110 1111 1112 1113 1114 1115 1116 1117 1118 1119 ... 1823